- Conditions
- Prostate Cancer Metastatic
- Interventions
- LY3023414, Enzalutamide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Homewood, Alabama • Fayetteville, Arkansas • Marina del Rey, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 862
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostatic Neoplasms
- Interventions
- CC-94676, CC1083611, CC1083610
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 19
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 14 more
- Conditions
- Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
- Interventions
- JANX013, JANX007
- Drug
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Atezolizumab, Enzalutamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 39
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone, JNJ-56021927
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- PROSTVAC-V/F, Nivolumab, Prostatectomy, Biopsy, Tylenol
- Biological · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
- Drug
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Other · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Portland, Oregon
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah • Seattle, Washington
- Conditions
- Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
- Interventions
- cediranib maleate, docetaxel, prednisone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Houston, Texas • Madison, Wisconsin
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- Sipuleucel-T Injection
- Drug
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 31
- States / cities
- Tuscon, Arizona • Duarte, California • Fresno, California + 28 more
- Conditions
- Prostate Cancer
- Interventions
- Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
- Biological · Drug
- Lead sponsor
- Cell Genesys
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 83
- States / cities
- Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more
- Conditions
- Prostatic Neoplasms
- Interventions
- CNTO 328, Docetaxel
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Everolimus, Enzalutamide
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- 177Lu-CYT-500
- Drug
- Lead sponsor
- Cytogen Corporation
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- BR-DIM
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Erdafitinib
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Pedro Barata, MD, MSc
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Sacituzumab Govitecan
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Madison, Wisconsin
- Conditions
- Metastatic Castrate-resistant Prostate Cancer, mCRPC
- Interventions
- Sipuleucel-T, Stereotactic Ablative Body Radiation
- Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Interventions
- AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
- Conditions
- Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
- Interventions
- YM155
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 7
- States / cities
- Tuscon, Arizona • Los Angeles, California • Coeur d'Alene, Idaho + 4 more
- Conditions
- Prostate Cancer
- Interventions
- recombinant interferon alfa, estramustine phosphate sodium, isotretinoin, mitoxantrone hydrochloride, paclitaxel, vinorelbine ditartrate
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 19
- States / cities
- Denver, Colorado • Atlanta, Georgia • Decatur, Georgia + 16 more